Is it safe to apply nystatin powder to an open wound under the breast?

Nystatin Powder Should NOT Be Applied to Open Wounds Under the Breast

Do not use nystatin powder on open wounds under the breast—the FDA label explicitly states it is not indicated for open wounds, and it should only be used for intact skin with candidal infections. 1

Why This Matters

The FDA labeling for nystatin topical powder is clear: it is indicated only for cutaneous or mucocutaneous mycotic infections caused by Candida species on intact skin 1. The precautions section explicitly states that "Nystatin Topical Powder should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections" 1, and the indication specifies cutaneous (skin surface) infections—not open wound infections.

The Critical Distinction

• Intact skin with candidal infection (intertrigo): This is the appropriate use for nystatin powder under the breast—when there is superficial fungal infection with redness, maceration, but no open wound
• Open wound: This requires different management entirely, focusing on wound healing principles first

What To Do Instead

If There Is Candidal Infection of Intact Skin (Intertrigo):

• Apply nystatin powder 2-3 times daily to the affected area 1
• Keep the area dry and reduce moisture/friction
• Consider barrier protection once infection clears

If There Is an Actual Open Wound:

1. First priority: Proper wound care with appropriate dressings, moisture management, and addressing underlying causes (pressure, friction, moisture)
2. If candidal infection is suspected in the wound: Confirm with culture/KOH prep 1
3. For documented candidal wound infection: Consider topical azoles (clotrimazole, miconazole) that have better evidence for wound application, or systemic antifungals if deep tissue involvement 2

Important Caveats

While there is limited research showing nystatin powder used successfully in severe burn wounds with angioinvasive fungal infections 3 and post-surgical wounds 4, these were specialized clinical scenarios with close monitoring. The FDA-approved indication remains for intact skin only 1.

The powder formulation can also create issues in open wounds by forming clumps and potentially interfering with wound healing—this is a practical concern beyond the regulatory indication.

If you suspect candidal involvement in an open wound, obtain cultures and consider systemic therapy or topical azoles rather than nystatin powder 2.